Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Clinical Trial ID NCT00265759

Rank	Title	Journal	Year	PubWeight™‹?›
1	Whole-genome analysis informs breast cancer response to aromatase inhibition.	Nature	2012	8.03
2	Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.	J Natl Cancer Inst	2011	6.11
3	Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.	J Clin Oncol	2011	2.71
4	Feasibility of feature-based indexing, clustering, and search of clinical trials. A case study of breast cancer trials from ClinicalTrials.gov.	Methods Inf Med	2013	0.99
5	A decade of letrozole: FACE.	Breast Cancer Res Treat	2007	0.90
6	Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers.	Nat Commun	2016	0.88
7	Estrogen receptor mutations and their role in breast cancer progression.	Breast Cancer Res	2014	0.86